Tag: Synthetic pregnane neuroactive steroid vomeropherine acting via nasal chemosensory receptor activation of olfactory-amygdala neural circuits

  • Itruvone

    Synthetic pregnane neuroactive steroid vomeropherine acting via nasal chemosensory receptor activation of olfactory-amygdala neural circuits

    A synthetic pregnane steroid pherine developed by Pherin Pharmaceuticals and advanced by VistaGen Therapeutics as an intranasal microgram-dose nasal spray for major depressive disorder, distinguished from all approved antidepressants by a proposed non-systemic mechanism of action operating through peripheral nasal chemosensory neuron activation of limbic-hypothalamic catecholaminergic circuits without requirement for blood-brain barrier penetration or direct central nervous system receptor engagement.

    Abstract

    Itruvone (PH10; pregn-4-en-20-yn-3-one; CAS 21321-89-1) is a synthetic neuroactive steroid of the pregnane class and the second clinical-stage pherine (vomeropherine) molecule, under development by VistaGen Therapeutics as an intranasal nasal spray for the treatment of major depressive disorder (MDD). The compound is structurally characterized by a 17-alpha-ethynyl substituent on the pregnane steroid nucleus and a 3-keto-4-ene A-ring motif, yielding an odorless crystalline material with a molecular weight of 296.45 g/mol and the molecular formula C21H28O. Itruvone is pharmacologically distinguished from all currently approved antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and the rapid-onset agents esketamine and brexanolone, by a proposed mechanism of action that does not require systemic absorption or direct activity on neuronal receptors in the brain.

    Preclinical tissue distribution studies using radiolabeled [14C]PH10 in rats demonstrated that a single intranasal administration was essentially undetectable in the brain and most other tissues, including blood and plasma, supporting the hypothesis that therapeutic activity occurs through peripheral chemosensory signaling rather than through systemic drug exposure. Preclinical electrophysiology studies further demonstrated that itruvone’s mechanism does not involve direct activation of GABA-A receptors in the brain, differentiating it from benzodiazepines and from the neurosteroid antidepressant brexanolone (allopregnanolone).

    The U.S. Food and Drug Administration has granted Fast Track designation for the development of itruvone as a potential treatment for MDD.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.